MiNK Therapeutics, Inc. — Q1 2022 Form 10-Q
Period: Three months ended March 31, 2022; unaudited. MiNK is a clinical-stage biotechnology company developing allogeneic iNKT cell therapies. It reported no revenue in the statements presented.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / prior balance |
|---|---|---|
| Research and development expense | $5.28 million | $3.10 million |
| General and administrative expense | $2.10 million | $0.59 million |
| Operating loss | $7.37 million | $3.01 million |
| Net loss | $7.78 million | $3.85 million |
| Basic and diluted loss per share | $0.23 | $0.16 |
| Cash used in operating activities | $4.20 million | $4.21 million |
| Cash and cash equivalents | $34.69 million | $38.89 million at Dec. 31, 2021 |
| Total assets | $36.14 million | $40.24 million at Dec. 31, 2021 |
| Current liabilities | $18.83 million | $16.47 million at Dec. 31, 2021 |
Operating margins are not meaningful because the filing reports no revenue. The company had a $90.7 million accumulated deficit and $17.3 million of stockholders’ equity at quarter-end. Current assets were $35.48 million. No bank debt is identified; the Agenus convertible note had converted to common shares in October 2021. Current liabilities include $7.04 million due to related parties and a $5.2 million repayable advance from the Belgium Walloon Region Government.
Changes and notable items
- R&D expense rose 70%, primarily with increased preclinical work, ongoing clinical trials and personnel costs. G&A expense rose 252%, reflecting personnel and stock-based compensation, and higher professional fees.
- Net loss approximately doubled year over year, while operating cash use was essentially flat. Cash declined by $4.20 million during the quarter.
- Q1 2022 included $0.79 million of share-based compensation. Q1 2021 included interest expense and a fair-value change related to the Agenus convertible note; the note was no longer outstanding in 2022.
- MiNK reported $0.52 million of foreign currency translation income in Q1 2022, reducing comprehensive loss to $7.25 million.
Outlook, risks and contingencies
- Management said the $34.7 million quarter-end cash balance was expected to fund requirements for more than one year from issuance of the financial statements. It expects continued operating losses and negative cash flows and may adjust spending to preserve liquidity. Additional funding could come from partnerships, debt or equity.
- Management expected AGENT-797 multiple-myeloma data in Q4 2022; preliminary solid-tumor trial readouts during 2022; GvHD trial initiation in 2022 and top-line data in the second half of 2022; and updated viral ARDS data later in 2022. The company also expected to initiate IND filings in 2022 for two preclinical engineered iNKT programs. These are forward-looking expectations, not guarantees.
- The $5.2 million Walloon Region advance relates to a discontinued research program. The company disputed the premise for repayment; whether any or all must be repaid remained uncertain.
- Material risks include clinical and regulatory uncertainty, trial delays or adverse results, manufacturing challenges, competition, dependence on third parties and Agenus, future financing needs and potential shareholder dilution. The filing reported no material legal proceedings and no material changes to the risk factors in its 2021 Form 10-K.
- Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported.
Key facts for investors to verify
- Progress, enrollment, safety and timing of AGENT-797 trials and anticipated data disclosures.
- Cash burn and runway against the company’s stated funding outlook, including the impact of clinical-development spending.
- Resolution and potential repayment obligations for the Walloon Region advance.
- Related-party balances, service charges and continuing reliance on Agenus for administrative support.
- Whether planned partnering or financing becomes necessary, and the terms and dilution implications if equity is issued.